Christopher Gibson, DO
Rheumatology · Ashton, IDNPI 1922501733
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.5%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. UCB, Inc. accounts for 62.8% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $11,918, more than ten times the $182 reported in 2019.
Across 377 payments — averaging $47.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$11K
- Amgen$2K
- AbbVie$995
- Novartis$577
- Johnson & Johnson$490
- AstraZeneca$390
- plus $2K from 25 others
Across 8 payments — averaging $2629.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$21K
What the payments were for
- Consulting fees$8,55047%
- Travel & lodging$1,4988%
- Food & beverage$7,54642%
- Education$4132%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 43 | $11,312 |
| Amgen(2 entities) | 148 | $2,006 |
| AbbVie | 45 | $995 |
| Novartis | 28 | $577 |
| Johnson & Johnson(2 entities) | 20 | $490 |
| AstraZeneca(2 entities) | 9 | $390 |
| Lilly USA, LLC | 12 | $351 |
| GSK | 12 | $239 |
| E.r. Squibb & Sons, L.L.C. | 11 | $204 |
| Janssen Scientific Affairs, LLC | 4 | $184 |
| Genentech USA, Inc. | 4 | $177 |
| Aurinia Pharma U.S., Inc. | 5 | $121 |
| Mallinckrodt Hospital Products Inc. | 2 | $118 |
| Pfizer | 6 | $117 |
| Radius Health, Inc. | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $89 |
| Bristol Myers Squibb | 5 | $86 |
| ANI Pharmaceuticals, Inc. | 3 | $84 |
| Ultragenyx Pharmaceutical Inc. | 3 | $70 |
| Octapharma USA, Inc. | 2 | $57 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $50 |
| Sandoz | 2 | $42 |
| Boehringer Ingelheim | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Sanofi | 1 | $18 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Celltrion USA Inc. | 1 | $15 |
| Pacira Pharmaceuticals Incorporated | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Organon | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,007 in reported general payments places this provider in the 85th percentile of 28 rheumatology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 56 | $500,849 |
| Humira(Cf)Adalimumab | 15 | $99,268 |
| Humira(Cf) PenAdalimumab | 14 | $92,618 |
| RinvoqUpadacitinib | 14 | $86,373 |
| Orencia ClickjectAbatacept | 14 | $85,637 |
| Hydroxychloroquine Sulfate | 256 | $7,610 |
| Leflunomide | 56 | $4,678 |
| Colchicine | 43 | $4,393 |
| Mycophenolate Mofetil | 27 | $3,609 |
| MethotrexateMethotrexate Sodium | 122 | $2,794 |
| Prednisone | 117 | $977 |
| Flurbiprofen | 13 | $673 |
| Celecoxib | 26 | $511 |
| Pregabalin | 13 | $244 |
| Methylprednisolone | 20 | $243 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf), Rinvoq | $995 | $185,64129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 rheumatology providers in Idaho.
Other rheumatology in Ashton
- Dustin DinningCoeur D Alene$311K
- William KnibbeBoise$164K
- Craig ScovilleIdaho Falls$26K
- James LovelessBoise$12K
- Peggy Ann RuppBoise$11K
- Craig WiesenhutterCoeur D Alene$7K
- Sean McMillanTwin Falls$4K
- Francis NardellaMeridian$3K
- Linda SakaiCoeur D Alene$3K
- Chara SolichMeridian$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.